Adiponectin (APM1) is an adipocyte-derived peptide. The APM1 gene is located on chromosome 3q27 and linked to type 2 diabetes. In patients with type 2 diabetes, the adiponectin level in plasma is decreased in comparison to healthy subjects. To identify genetic defects of the APM1 gene that contribute to the development of type 2 diabetes, we genotyped 13 single nucleotide polymorphisms (SNPs) in 106 patients with type 2 diabetes, 325 patients with impaired glucose tolerance (IGT), and 497 nondiabetic control subjects in Swedish Caucasians by using dynamic allele-specific hybridization (DASH). We found that SNPs −11426(A/G) and −11377(G/C) in the proximal promoter region had significant differences of allele frequencies between type 2 diabetic patients and nondiabetic control subjects (P = 0.02 and P = 0.04, respectively). SNP-11426(A/G) was significantly associated with fasting plasma glucose in type 2 diabetic patients (P = 0.02) and in IGT subjects (P = 0.04), while the patients carrying CC and CG genotypes for SNP-11377(G/C) had a higher BMI than the patients with the GG genotype (P = 0.03). Haplotype analysis of 13 SNPs in the APM1 gene showed that estimates of haplotype frequencies in Swedish Caucasians are similar to those estimated in French Caucasians. However, no significant association of haplotypes with type 2 diabetes and IGT was detected in our study. The present study provides additional evidence that SNPs in the proximal promoter region of the APM1 gene contribute to the development of type 2 diabetes.

Adiponectin (APM1, also known as ACRP30, GBP28, or AdipoQ) is secreted from adipose tissue and regulates insulin sensitivity (1,2). The APM1 gene has been identified and is located on chromosome 3q27 (3–5). In this chromosome region, genome-wide scans have revealed a susceptibility locus for type 2 diabetes (6), coronary heart disease (7), and measures of adiposity (8). Several studies have demonstrated that the adiponectin level in plasma is decreased in patients with type 2 diabetes or obesity in comparison to healthy subjects (9,10). Thus, adiponectin may play a role in the pathogenesis of type 2 diabetes and insulin resistance. Recently, mutation screening of the APM1 gene in Japanese and French populations was performed, and 13 single nucleotide polymorphisms (SNPs) were found in the APM1 gene (11,12). SNPs +45T/G and +276G/T in exon 2 and intron 2, respectively, of the APM1 gene were found to be significantly associated with type 2 diabetes in Japanese patients with normal body weight (BMI <24 kg/m2) mainly due to decreased insulin sensitivity (11). Stumvoll et al. (13) demonstrated that SNP +45T/G in the APM1 gene increases the risk for obesity and secondarily for insulin resistance in nondiabetic Caucasians of German ancestry. Furthermore, in another group of nondiabetic Caucasians, a haplotype defined by SNPs +45T/G and +276G/T was strongly associated with many components of the insulin resistance syndrome (14).

A recent report from French Caucasians predicted no association of SNPs +45T/G and +276G/T with type 2 diabetes. The haplotype including SNPs −11391G/A and −11377C/G in the proximal promoter region of the APM1 gene was strongly associated with adiponectin levels in the plasma and type 2 diabetes. However, the authors failed to detect association with insulin resistance indexes (12). In the present study, we performed a genetic association study for 13 SNPs in the APM1 gene in patients with type 2 diabetes, subjects with impaired glucose tolerance (IGT), and nondiabetic healthy individuals of Swedish ancestry. This may provide further evidence to evaluate the contribution of genetic variation of the APM1 gene in the development of type 2 diabetes.

Subjects.

We studied 106 (50 women and 56 men) type 2 diabetic patients and 325 (158 women and 167 men) IGT subjects randomly selected from each family and 497 (250/249) unrelated nondiabetic control subjects. All were Swedes selected from the Stockholm Diabetes Prevention Program and were sex- and age-matched between case subjects (type 2 diabetic patients and IGT subjects) and nondiabetic control subjects. Type 2 diabetic patients and IGT subjects were diagnosed according to the 1985 World Health Organization criteria. The nondiabetic control subjects had normal birth weight, normal BMI (<25 kg/m2), and no relatives with type 2 diabetes. Concentrations of plasma glucose, plasma insulin, and other clinical characteristics were measured as previously described. Clinical characteristics of the type 2 diabetic patients, IGT subjects, and nondiabetic control subjects are summarized in Table 1. Informed consent was obtained from all subjects, and the study was approved by the local ethics committees. Genomic DNA was extracted from peripheral blood using a Puregene DNA purification kit (Gentra).

Insulin resistance index measurements.

Insulin resistance was assessed by homeostasis model assessment (HOMA) (15). The HOMA index for insulin resistance (HOMA-IR) was then calculated in the present study by using the following formula: fasting plasma glucose (mmol/l) × fasting plasma insulin (mU/ml)/22.5.

SNP identification numbers of APM1 in HGVbase.

All SNPs found by mutation screening of a French population (12) are recorded in the SNP database called HGVbase. The SNP identification numbers and detailed sequence information (25 bp in each direction around SNP) are publicly available in this database (http://hgvbase.cgb.ki.SE).

PCR-dynamic allele-specific hybridization (DASH) assay design and genotyping.

We have used a high throughput SNP scoring technique called dynamic allele-specific hybridization (DASH) (16). PCR-DASH assay design and SNP genotyping protocol were used as described previously (17). (The sequences of primers and probes designed for PCR-DASH and optimized PCR conditions are available in the supplemental data [Table 1]).

Statistical analyses.

The distribution of the alleles of each SNP was tested for the Hardy-Weinberg equilibrium. Logistic regression was used to test for differences in allele frequencies and clinical features between case subjects (type 2 diabetic patients and IGT subjects) and nondiabetic control subjects. We obtained estimates of pairwise linkage disequilibrium values |D′| (18) using the software 2LD. The haplotype estimation was carried out using the Estimation Haplotype program (EH-plus) (ftp://linkage.rockefeller.edu/software/eh) (19,20). Differences in clinical and metabolic variables between individuals with different genotypes were tested by Student’s t tests and ANOVA using the BMDP statistical software version 1.12 (Los Angeles, CA).

We have performed genotyping for 13 SNPs of the APM1 gene in 106 Swedish patients with type 2 diabetes, 325 subjects with IGT, and 497 nondiabetic control subjects. All participants were selected from the Stockholm Diabetes Prevention Program and were clinically well characterized. The 13 SNPs in the APM1 gene were reported previously in Japanese and French populations (11,12). Genotype distributions for the 13 SNPs studied in our population were in the Hardy-Weinberg equilibrium. The allele frequencies of SNPs in the APM1 gene in type 2 diabetic patients, IGT subjects, and nondiabetic control subjects are summarized in Table 2.

The proximal promoter region of the APM1 gene includes 5′-untranslated region (UTR), exon 1, and intron 1. In this region, five SNPs including −11426(A/G), −11391(G/A), −11377(G/C), −4041(A/C), and −3971(A/G) were genotyped. For SNP −11426 (A/G), which is located in the 5′-UTR, type 2 diabetic patients had a significantly higher G allele frequency in comparison to nondiabetic control subjects (0.184/0.816 vs. 0.087/0.913, P = 0.02). Table 3 shows the clinical characteristics of patients with type 2 diabetes, subjects with IGT, and nondiabetic control subjects according to genotypes of SNP −11426(A/G). The diabetic patients with AG and GG genotypes had significantly higher fasting plasma glucose levels in comparison to those patients carrying the AA genotype (9.1 ± 5.1 and 10.2 ± 6.7 vs. 7.5 ± 2.5 mmol/l, P = 0.02). Similarly, the carriers of AG and GG genotypes in IGT subjects had a statistically significantly higher fasting plasma glucose level than the carriers of the AA genotype (5.5 ± 0.7 and 5.4 ± 0.5 vs. 5.3 ± 0.7 mmol/l, P = 0.04). For SNP −11377(G/C), which is also located on the 5′-UTR, a significant difference of allele frequencies between type 2 diabetic patients (0.745/0.255) and nondiabetic control subjects (0.674/0.326, P = 0.04) was found. Table 3 also summarizes the clinical features of type 2 diabetic patients, IGT subjects, and nondiabetic control subjects with the genotypes of SNP −11377(G/C). The results indicated that type 2 diabetic patients with CC and CG genotypes had a statistically significantly higher BMI than the patients with the GG genotype (31.2 ± 6.4 and 29.9 ± 5.2 vs. 27.3 ± 3.6 kg/m2, P = 0.03).

There are three nonsynonymous SNPs [G84R(G/C), G90S(G/A), and Y111H(T/C)] in exon 3 of the APM1 gene. We found that these three SNPs had low allele frequencies and were not associated with type 2 diabetes or IGT.

We have carried out a haplotype analysis for the 13 genotyped SNPs of the APM1 gene. There is a strong linkage disequilibrium across the gene (see the supplemental data, Table 2), as was reported for the French Caucasians study (12). Furthermore, estimates of haplotype frequencies for our samples are similar to those estimated for French Caucasians (comparison of haplotype frequencies between French and Swedish Caucasians is shown in the supplemental data, Table 3). To see if we could obtain statistically significant estimates of association with diagnosis compared with those obtained by SNP analysis, we tested for haplotype association in all 2-SNP haplotypes and comparatively analyzed the significances between case subjects (the patients with type 2 diabetes and the subjects with IGT together or separated in each group) and nondiabetic control subjects. However, we found no statistically significant associations.

The purpose of the present study was to examine the contribution of the APM1 gene in the development of type 2 diabetes in Swedish Caucasians. We have genotyped 13 SNPs in the APM1 gene, which have been reported in a Japanese population and in French Caucasians. Additional mutations (i.e., R112C, I1164T, R221S, and H241P) that were subsequently reported in a Japanese population (21) were not detected in the present study. We found that SNP −11426(A/G) is strongly associated with increased fasting plasma glucose levels in type 2 diabetes and IGT. In another SNP −11377(G/C), the C allele may contribute a genetic risk for increasing body weight in type 2 diabetes. The present study indicated that these two SNPs in the proximal promoter region of the APM1 gene are associated with type 2 diabetes in Swedish Caucasians.

In addition to the present study, other studies have reported that SNPs in the APM1 gene had a strong association with type 2 diabetes in the Japanese population, as well as in German, French, and American Caucasians (11–14). Figure 1 represents localization of SNPs in the APM1 gene and genetic association with type 2 diabetes and/or insulin resistance in five populations. SNPs +45G15G and +276(G/T) had a strong association with insulin resistance in Japanese type 2 diabetic patients (11). The SNP +45G15G, either independently or as a haplotype together with SNP +276(G/T), was associated with obesity and insulin resistance in German and American Caucasians (13,14). However, the association of these two SNPs with type 2 diabetes and insulin resistance was not seen in French Caucasians (12) as well as in the present study. Instead, a haplotype including SNPs −11391(G/A) and −11377(G/C) in the proximal promoter region was found to be associated with adiponectin levels and with type 2 diabetes in French Caucasians (12). In the present study, we detected that SNP −11377(G/C) may contribute to the genetic risk for BMI in type 2 diabetes. Furthermore, we have found that another SNP [−11426(A/G)] in the proximal promoter region is associated with fasting plasma glucose in type 2 diabetes in Swedish Caucasians. Thus, our study is mainly consistent with the recent report from French Caucasians (12) and provides further evidence that SNPs in the proximal promoter region of the APM1 gene are associated with type 2 diabetes.

Type 2 diabetes is a complex disease. The pathogenesis of type 2 diabetes and the metabolic syndrome are not fully clarified, but the interaction between genetic factors and environmental triggers is important. Genetic association between the SNPs of candidate genes and type 2 diabetes may not be fully explained by a single population study. The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ gene is found to associate with a decreased risk for type 2 diabetes (22). In different populations, however, the association for other genes, such as calpain 10, have been replicated in some but not all studies (23). This may be due to differences in geographic and haplotype structures of candidate type 2 diabetes susceptibility variants in this gene (24). Variants in the APM1 gene have been associated with type 2 diabetes and/or insulin resistance in five different populations, including a Japanese population and German, French, American, and Swedish Caucasians. However, the susceptibility SNPs of this gene for type 2 diabetes and/or insulin resistance are different in different populations. This may reveal that the genetic defects of SNPs in the APM1 gene are influenced by genetic backgrounds and environmental factors in different ethnic populations.

FIG. 1.
FIG. 1. Localization of SNPs in the APM1 gene and genetic association with type 2 diabetes and/or insulin resistance in five populations.
View largeDownload slide

Localization of SNPs in the APM1 gene and genetic association with type 2 diabetes and/or insulin resistance in five populations.

FIG. 1.
FIG. 1. Localization of SNPs in the APM1 gene and genetic association with type 2 diabetes and/or insulin resistance in five populations.
View largeDownload slide

Localization of SNPs in the APM1 gene and genetic association with type 2 diabetes and/or insulin resistance in five populations.

Close modal
TABLE 1

Clinical characteristics of Swedish type 2 diabetic patients, IGT subjects, and nondiabetic control subjects

Type 2 diabetic patientsIGT subjectsNondiabetic control subjects
n (F/M) 106 (50/56) 325 (158/167) 497 (250/247) 
Age (years) 51 ± 4 50 ± 5 48 ± 5 
BMI (kg/m2) 30.3 ± 5.9* 29.0 ± 5.4* 23.2 ± 2.0 
Waist-to-hip ratio 0.92 ± 0.07* 0.89 ± 0.08* 0.82 ± 0.06 
Systolic blood pressure (mmHg) 136 ± 16* 134 ± 18* 118 ± 12 
Diastolic blood pressure (mmHg) 84 ± 10* 84 ± 11* 74 ± 9 
Fasting plasma glucose (mmol/l) 7.8 ± 3.3* 5.3 ± 0.7* 4.5 ± 0.5 
2-h plasma glucose (mmol/l) 14.1 ± 3.9* 8.7 ± 1.2* 4.2 ± 1.3 
Fasting plasma insulin (pmol/l) 30.6 ± 20.4* 21.3 ± 11.5* 13.4 ± 7.8 
2-h plasma insulin (pmol/l) 101.4 ± 74.7* 114.8 ± 111.7* 36.3 ± 25.9 
HOMA-IR index† 10.6 ± 8.3* 5.1 ± 3.0* 2.7 ± 1.8 
Type 2 diabetic patientsIGT subjectsNondiabetic control subjects
n (F/M) 106 (50/56) 325 (158/167) 497 (250/247) 
Age (years) 51 ± 4 50 ± 5 48 ± 5 
BMI (kg/m2) 30.3 ± 5.9* 29.0 ± 5.4* 23.2 ± 2.0 
Waist-to-hip ratio 0.92 ± 0.07* 0.89 ± 0.08* 0.82 ± 0.06 
Systolic blood pressure (mmHg) 136 ± 16* 134 ± 18* 118 ± 12 
Diastolic blood pressure (mmHg) 84 ± 10* 84 ± 11* 74 ± 9 
Fasting plasma glucose (mmol/l) 7.8 ± 3.3* 5.3 ± 0.7* 4.5 ± 0.5 
2-h plasma glucose (mmol/l) 14.1 ± 3.9* 8.7 ± 1.2* 4.2 ± 1.3 
Fasting plasma insulin (pmol/l) 30.6 ± 20.4* 21.3 ± 11.5* 13.4 ± 7.8 
2-h plasma insulin (pmol/l) 101.4 ± 74.7* 114.8 ± 111.7* 36.3 ± 25.9 
HOMA-IR index† 10.6 ± 8.3* 5.1 ± 3.0* 2.7 ± 1.8 

Data are means ± SD.

*

P < 0.001 vs. control subjects.

†

Insulin resistance index was calculated by HOMA.

View Large
TABLE 2

Allele frequencies of 13 SNPs of the APM1 gene in Swedish type 2 diabetic patients, IGT subjects, and nondiabetic control subjects

SNP identification number in HGV baseSNP type and locationType 2 diabetic patientsIGT subjectsNondiabetic control subjects
SNP001026434 −11426 (A/G) promoter G 0.184/A 0.816* G 0.098/A 0.902 G 0.087/A 0.913 
SNP001026435 −11391 (G/A) promoter G 0.941/A 0.059 G 0.935/A 0.065 G 0.938/A 0.062 
SNP000585775 −11377 (G/C) promoter G 0.745/C 0.255* G 0.715/C 0.285 G 0.674/C 0.326 
SNP000149612 −4041 (A/C) intron 1 C 0.342/A 0.658 C 0.334/A 0.666 C 0.319/A 0.681 
SNP000149613 −3971 (A/G) intron 1 A 0.824/G 0.176 A 0.822/G 0.178 A 0.850/G 0.150 
SNP001026437 +45 G15G (T/G) exon 2 T 0.903/G 0.097 T 0.910/G 0.090 T 0.915/G 0.085 
SNP000162557 +276 (G/T) intron 2 G 0.688/T 0.312 G 0.709/T 0.291 G 0.708/T 0.292 
SNP001026438 +349 (A/G) intron 2 G 0.045/A 0.955 G 0.063/A 0.937 G 0.072/A 0.928 
SNP001026439 +712 (G/A) intron 2 G 0.600/A 0.400 G 0.630/A 0.370 G 0.632/A 0.368 
SNP001026441 G84R (G/C) exon 3 G 1.000/C 0.000 G 0.997/C 0.003 G 0.994/C 0.006 
SNP001026442 G90S (G/A) exon 3 A 0.980/G 0.020 A 0.981/G 0.019 A 0.980/G 0.020 
SNP001026443 Y111H (T/C) exon 3 T 0.972/C 0.028 T 0.984/C 0.016 T 0.975/C 0.025 
SNP001026440 +2019 (A/−) 3′-UTR A 0.600/N 0.400 A 0.620/N 0.380 A 0.619/N 0.381 
SNP identification number in HGV baseSNP type and locationType 2 diabetic patientsIGT subjectsNondiabetic control subjects
SNP001026434 −11426 (A/G) promoter G 0.184/A 0.816* G 0.098/A 0.902 G 0.087/A 0.913 
SNP001026435 −11391 (G/A) promoter G 0.941/A 0.059 G 0.935/A 0.065 G 0.938/A 0.062 
SNP000585775 −11377 (G/C) promoter G 0.745/C 0.255* G 0.715/C 0.285 G 0.674/C 0.326 
SNP000149612 −4041 (A/C) intron 1 C 0.342/A 0.658 C 0.334/A 0.666 C 0.319/A 0.681 
SNP000149613 −3971 (A/G) intron 1 A 0.824/G 0.176 A 0.822/G 0.178 A 0.850/G 0.150 
SNP001026437 +45 G15G (T/G) exon 2 T 0.903/G 0.097 T 0.910/G 0.090 T 0.915/G 0.085 
SNP000162557 +276 (G/T) intron 2 G 0.688/T 0.312 G 0.709/T 0.291 G 0.708/T 0.292 
SNP001026438 +349 (A/G) intron 2 G 0.045/A 0.955 G 0.063/A 0.937 G 0.072/A 0.928 
SNP001026439 +712 (G/A) intron 2 G 0.600/A 0.400 G 0.630/A 0.370 G 0.632/A 0.368 
SNP001026441 G84R (G/C) exon 3 G 1.000/C 0.000 G 0.997/C 0.003 G 0.994/C 0.006 
SNP001026442 G90S (G/A) exon 3 A 0.980/G 0.020 A 0.981/G 0.019 A 0.980/G 0.020 
SNP001026443 Y111H (T/C) exon 3 T 0.972/C 0.028 T 0.984/C 0.016 T 0.975/C 0.025 
SNP001026440 +2019 (A/−) 3′-UTR A 0.600/N 0.400 A 0.620/N 0.380 A 0.619/N 0.381 

Significance (P value) for allele frequency differences in type 2 diabetic patients or IGT subjects versus nondiabetic control subjects.

*

P < 0.05.

View Large
TABLE 3

Clinical characteristics of type 2 diabetic patients, IGT subjects, and nondiabetic control subjects according to the genotypes of SNP −11426(A/G) and SNP −11377(G/C)

nBMI (kg/m2)Fasting plasma glucose (mmol/l)Fasting plasma insulin (pmol/l)HOMA-IR index
SNP −11426 (A/G) genotypes      
 All type 2 diabetic patients      
  AA 79 30.3 ± 6.1 7.5 ± 2.5 29.6 ± 20.8 10.1 ± 8.5 
  AG 22 30.6 ± 5.5 9.1 ± 5.1 30.6 ± 22.3 11.1 ± 8.5 
  GG 2 30.2 ± 1.7 10.2 ± 6.7 24.5 ± 16.3 8.6 ± 0.2 
  P value (AA vs. AG + GG) — 0.40 0.02 0.16 0.09 
 All IGT subjects      
  AA 257 28.8 ± 5.8 5.3 ± 0.7 20.1 ± 11.5 4.8 ± 3.0 
  AG 57 29.5 ± 4.9 5.5 ± 0.7 22.5 ± 13.1 5.6 ± 3.3 
  GG 2 28.4 ± 0.9 5.4 ± 0.5 15.0 ± 4.2 3.5 ± 1.3 
  P value (AA vs. AG + GG) — 0.81 0.04 0.84 0.61 
 Nondiabetic control subjects      
  AA 416 23.0 ± 2.6 4.5 ± 0.5 13.1 ± 8.2 2.7 ± 1.9 
  AG 70 23.5 ± 1.6 4.6 ± 0.4 14.0 ± 6.2 2.9 ± 1.4 
  GG 8 22.6 ± 1.5 4.5 ± 0.4 9.5 ± 5.0 2.9 ± 1.0 
  P value (AA vs. AG + GG) — 0.12 0.36 0.72 0.40 
SNP −11377 (G/C) genotypes      
 All type 2 diabetic patients      
  CC 58 31.2 ± 6.4 7.8 ± 2.9 31.7 ± 23.2 11.2 ± 9.4 
  CG 34 29.9 ± 5.2 8.2 ± 4.2 26.9 ± 17.3 9.4 ± 7.0 
  GG 11 27.3 ± 3.6 6.9 ± 1.7 21.5 ± 14.7 6.4 ± 4.5 
  P value (CC vs. CG + GG) — 0.03 0.35 0.51 0.31 
 All IGT subjects      
  CC 155 29.0 ± 5.4 5.3 ± 0.7 21.2 ± 12.1 5.0 ± 3.1 
  CG 143 28.9 ± 6.5 5.4 ± 0.8 20.8 ± 12.1 5.1 ± 3.2 
  GG 16 28.6 ± 4.4 5.1 ± 0.7 16.1 ± 9.1 3.7 ± 2.2 
  P value (CC vs. CG + GG) — 0.77 0.34 0.11 0.75 
 Nondiabetic control subjects      
  CC 247 23.4 ± 2.2 4.6 ± 0.5 13.7 ± 8.4 2.8 ± 1.9 
  CG 186 22.9 ± 2.5 4.5 ± 0.5 12.7 ± 6.5 2.6 ± 1.4 
  GG 53 22.7 ± 1.9 4.5 ± 0.5 12.3 ± 10.1 2.4 ± 2.2 
  P value (CC vs. CG + GG) — 0.06 0.19 0.65 0.51 
nBMI (kg/m2)Fasting plasma glucose (mmol/l)Fasting plasma insulin (pmol/l)HOMA-IR index
SNP −11426 (A/G) genotypes      
 All type 2 diabetic patients      
  AA 79 30.3 ± 6.1 7.5 ± 2.5 29.6 ± 20.8 10.1 ± 8.5 
  AG 22 30.6 ± 5.5 9.1 ± 5.1 30.6 ± 22.3 11.1 ± 8.5 
  GG 2 30.2 ± 1.7 10.2 ± 6.7 24.5 ± 16.3 8.6 ± 0.2 
  P value (AA vs. AG + GG) — 0.40 0.02 0.16 0.09 
 All IGT subjects      
  AA 257 28.8 ± 5.8 5.3 ± 0.7 20.1 ± 11.5 4.8 ± 3.0 
  AG 57 29.5 ± 4.9 5.5 ± 0.7 22.5 ± 13.1 5.6 ± 3.3 
  GG 2 28.4 ± 0.9 5.4 ± 0.5 15.0 ± 4.2 3.5 ± 1.3 
  P value (AA vs. AG + GG) — 0.81 0.04 0.84 0.61 
 Nondiabetic control subjects      
  AA 416 23.0 ± 2.6 4.5 ± 0.5 13.1 ± 8.2 2.7 ± 1.9 
  AG 70 23.5 ± 1.6 4.6 ± 0.4 14.0 ± 6.2 2.9 ± 1.4 
  GG 8 22.6 ± 1.5 4.5 ± 0.4 9.5 ± 5.0 2.9 ± 1.0 
  P value (AA vs. AG + GG) — 0.12 0.36 0.72 0.40 
SNP −11377 (G/C) genotypes      
 All type 2 diabetic patients      
  CC 58 31.2 ± 6.4 7.8 ± 2.9 31.7 ± 23.2 11.2 ± 9.4 
  CG 34 29.9 ± 5.2 8.2 ± 4.2 26.9 ± 17.3 9.4 ± 7.0 
  GG 11 27.3 ± 3.6 6.9 ± 1.7 21.5 ± 14.7 6.4 ± 4.5 
  P value (CC vs. CG + GG) — 0.03 0.35 0.51 0.31 
 All IGT subjects      
  CC 155 29.0 ± 5.4 5.3 ± 0.7 21.2 ± 12.1 5.0 ± 3.1 
  CG 143 28.9 ± 6.5 5.4 ± 0.8 20.8 ± 12.1 5.1 ± 3.2 
  GG 16 28.6 ± 4.4 5.1 ± 0.7 16.1 ± 9.1 3.7 ± 2.2 
  P value (CC vs. CG + GG) — 0.77 0.34 0.11 0.75 
 Nondiabetic control subjects      
  CC 247 23.4 ± 2.2 4.6 ± 0.5 13.7 ± 8.4 2.8 ± 1.9 
  CG 186 22.9 ± 2.5 4.5 ± 0.5 12.7 ± 6.5 2.6 ± 1.4 
  GG 53 22.7 ± 1.9 4.5 ± 0.5 12.3 ± 10.1 2.4 ± 2.2 
  P value (CC vs. CG + GG) — 0.06 0.19 0.65 0.51 

Data are means ± SD. The P values for fasting plasma glucose, insulin, and HOMA-IR index were adjusted for BMI.

View Large

Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org.

This article is based on a presentation at a symposium. The symposium and the publication of this article were made possible by an unrestricted educational grant from Les Laboratoires Servier.

The work was supported by the Novo Nordic Consortium, the Swedish Research Council, the Vetenskapligt Arbete Inom Diabetologi Foundation, the Loo and Hans Osterman Foundation, and the Swedish Diabetes Association.

The authors thank all subjects for participating in the present study, Drs. Philippe Froguel and Francis Vasseur for SNP information, Dr. Yudi Pawitan for valuable discussion in statistical analysis, and Yvonne Strömberg for excellent assistance.

1.
Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity.
J Biol Chem
 
271
:
10697
–10703,
1996
2.
Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript).
Biochem Biophys Res Commun
 
221
:
286
–289,
1996
3.
Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma.
J Biochem
 
120
:
803
–812,
1996
4.
Saito K, Tobe T, Minoshima S, Asakawa S, Sumiya J, Yoda M, Nakano Y, Shimizu N, Tomita M: Organization of the gene for gelatin-binding protein (GBP28).
Gene
 
229
:
67
–73,
1999
5.
Schaffler A, Langmann T, Palitzsch KD, Scholmerich J, Schmitz G: Identification and characterization of the human adipocyte apM-1 promoter.
Biochim Biophys Acta
 
1399
:
187
–197,
1998
6.
Vionnet N, Hani E-H, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Lepretre F, Lecoeur C, Gallina P, Zekiri L, Dina C, Froguel P: Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21–q24.
Am J Hum Genet
 
67
:
1470
–1480,
2000
7.
Francke S, Manraj M, Lacquemant C, Lecoeur C, Lepretre F, Passa P, Hebe A, Corset L, Yan SL, Lahmidi S, Jankee S, Gunness TK, Ramjuttun US, Balgobin V, Dina C, Froguel P: A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27.
Hum Mol Genet
 
10
:
2751
–2765,
2001
8.
Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, Marks JA, Krakower GR, Jacob HJ, Weber J, Martin L, Blangero J, Comuzzie AG: Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome.
Proc Natl Acad Sci U S A
 
97
:
14478
–14483,
2000
9.
Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, Rafaeloff-Phail R, Seng T, Suter TM, Sluka JP, Ravussin E, Gadski RA, Caro JF: Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes.
Int J Exp Diabetes Res
 
1
:
81
–88,
2000
10.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.
Biochem Biophys Res Commun
 
257
:
79
–83,
1999
11.
Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Kimura S, Tomita M, Kimura S, Ito C, Froguel P, Kadowaki T: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population.
Diabetes
 
51
:
536
–540,
2002
12.
Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, Boutin P, Lepretre L, Dupont S, Hara K, Kadowaki T, Froguel P: Single nucleotide polymorphisms haplotypes in the both proximal promoter and exon 3 of APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians.
Hum Mol Genet
 
11
:
2607
–2614,
2002
13.
Stumvoll M, Tschritter O, Fritsche A, Staiger H, Renn W, Weisser M, Machicao F, Haring H: Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes.
Diabetes
 
51
:
37
–41,
2002
14.
Menzaghi C, Ercolino T, Paola RD, Berg AH, Waaram JH, Scherer PE, Trischitta V, Doria A: A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome.
Diabetes
 
51
:
2306
–2312,
2002
15.
Matthews DR, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
Diabetologia
 
28
:
412
–419,
1985
16.
Howell MW, Jobs M, Gyllensten U, Brookes AJ: Dynamic allele-specific hybridisation: a new method for scoring single nucleotide polymorphisms.
Nat Biotech
 
17
:
87
–88,
1999
17.
Prince JA, Feuk L, Howell WM, Jobs M, Emahazion T, Blennow K, Brookes AJ: Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation.
Genome Res
 
11
:
152
–162,
2001
18.
Lewontin RC: On measure of gametic disequilibrium.
Genet
 
120
:
849
–852,
1988
19.
Terwilliger J, Ott J:
Handbook of Human Genetic Linkage
. Baltimore, MD, Johns Hopkins University,
1994
20.
Xie X, Ott J: Testing linkage disequilibrium between a disease gene and marker loci.
Am J Hum Genet
 
53
:
1107
,
1993
21.
Kondo H, Shimomura I, Matsukawa Y, Kumada M, Takahashi M, Matsuda M, Ouchi N, Kihara S, Kawamoto T, Sumitsuji S, Funahashi T, Matsuzawa Y: Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome.
Diabetes
 
51
:
2325
–2328,
2002
22.
Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.
Nat Genet
 
26
:
76
–80,
2000
23.
Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz PE, del Bosque-Plata L, Horikawa Y, Oda Y, Yoshiuchi I, Colilla S, Polonsky KS, Wei S, Concannon P, Iwasaki N, Schulze J, Baier LJ, Bogardus C, Groop L, Boerwinkle E, Hanis CL, Bell GI: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus.
Nat Genet
 
26
:
163
–175,
2000
24.
Fullerton SM, Bartoszewicz A, Ybazeta G, Horikawa Y, Bell GI, Kidd KK, Cox NJ, Hudson RR, Di Rienzo A: Geographic and haplotype structure of candidate type 2 diabetes susceptibility variants at the calpain-10 locus.
Am J Hum Genet
 
70
:
1096
–1106,
2002
DIABETES
2004